Visit Us @
Synergy Centre TU Dublin, Tallaght, D24A386
Mail Us @
info@codlad.com
Call Us @
+353 851890752

FDA

Coronavirus (COVID-19) Update: FDA to Hold Advisory Committee Meeting on COVID-19 Vaccines to Discuss Future Boosters

March 21, 2022

Coronavirus (COVID-19) Update: FDA to Hold Advisory Committee Meeting on COVID-19 Vaccines to Discuss Future Boosters

Today, the U.S. Food and Drug Administration is announcing a virtual meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Wed., April…

Coronavirus (COVID-19) Update: FDA to Hold Advisory Committee Meeting on COVID-19 Vaccines to Discuss Future Boosters FDA
FDA Roundup: March 18, 2022

March 18, 2022

FDA Roundup: March 18, 2022

Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On March 18, the FDA added the…

FDA Roundup: March 18, 2022 FDA
FDA, Reagan-Udall Foundation to Hold Important Public Workshop to Discuss Naloxone Access

March 17, 2022

FDA, Reagan-Udall Foundation to Hold Important Public Workshop to Discuss Naloxone Access

The U.S. Food and Drug Administration will host a virtual public workshop on Mar. 29, to discuss critical questions around access to naloxone, a drug…

FDA, Reagan-Udall Foundation to Hold Important Public Workshop to Discuss Naloxone Access FDA
FDA Roundup: March 15, 2022

March 15, 2022

FDA Roundup: March 15, 2022

Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA is announcing the availability…

FDA Roundup: March 15, 2022 FDA
FDA Approves First Generic of Symbicort to Treat Asthma and COPD

March 15, 2022

FDA Approves First Generic of Symbicort to Treat Asthma and COPD

Today, the U.S. Food and Drug Administration approved the first generic of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of two…

FDA Approves First Generic of Symbicort to Treat Asthma and COPD FDA
FDA Makes Low-Risk Determination for Marketing of Products from Genome-Edited Beef Cattle After Safety Review

March 7, 2022

FDA Makes Low-Risk Determination for Marketing of Products from Genome-Edited Beef Cattle After Safety Review

Today, the U.S. Food and Drug Administration announced it has made a low-risk determination for the marketing of products, including food, from two genome-edited beef…

FDA Makes Low-Risk Determination for Marketing of Products from Genome-Edited Beef Cattle After Safety Review FDA
FDA Roundup: March 4, 2022

March 4, 2022

FDA Roundup: March 4, 2022

Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA published the FDA Voices:…

FDA Roundup: March 4, 2022 FDA
FDA Urges Companies to be ’Recall Ready’ to Protect Public Health as Part of Final Guidance for Voluntary Recalls

March 3, 2022

FDA Urges Companies to be ’Recall Ready’ to Protect Public Health as Part of Final Guidance for Voluntary Recalls

Today, the U.S. Food and Drug Administration finalized guidance to help companies prepare to quickly and effectively remove violative products from the market. The guidance…

FDA Urges Companies to be ’Recall Ready’ to Protect Public Health as Part of Final Guidance for Voluntary Recalls FDA
FDA Clinical Trial Guidances Share Biden Administration’s Goals for Advancing Development of Cancer Treatments

March 1, 2022

FDA Clinical Trial Guidances Share Biden Administration’s Goals for Advancing Development of Cancer Treatments

Today, the U.S. Food and Drug Administration issued three final guidances to industry regarding cancer clinical trials that parallel the goals of President Biden’s recently…

FDA Clinical Trial Guidances Share Biden Administration’s Goals for Advancing Development of Cancer Treatments FDA
FDA Roundup: February 25, 2022

February 25, 2022

FDA Roundup: February 25, 2022

Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Feb. 24, the FDA issued an…

FDA Roundup: February 25, 2022 FDA

Latest Posts

FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome
FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome
March 25, 2026
FDA Schedules Public Meeting on the Commissioner’s National Priority Voucher Pilot Program
FDA Schedules Public Meeting on the Commissioner’s National Priority Voucher Pilot Program
March 20, 2026
FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide
FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide
March 19, 2026